Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM/LdT+ADV. Methods: This prospective randomized controlled trial examined 91 patients whose serum HBV DNA levels were greater than 60 IU/mL after at least 24 weeks of treatment with LAM/LdT+ADV for LAM-resistant HBV. Patients were randomized to receive a new treatment (ETV+TDF, n=45) or maintained on the same treatment (LAM/LdT+ADV, n=46) for 48 weeks. Patients with baseline ADV resistance were excluded. Results: Compared to LAM/LdT+ADV group, ETV+TDF group had more patients with a virologic response (42/45 [93.33%] vs. 3/46 [6.52%], P<0.001) and had a greater mean reduction in serum HBV DNA level from baseline (-4.16 vs. -0.37 log10 IU/mL, P<0.001). Multivariate analysis indicated that high baseline HBV DNA level (P=0.005) and LAM/LdT+ADV maintenance therapy (P=0.001) were negatively associated with virologic response. At week 48, additional ADV- or ETVassociated mutations were cleared in ETV+TDF group, but such mutations were present in 4.3% of patients in LAM/ LdT+ADV group (P=0.106). The two groups had similar rates of adverse events. Conclusions: ETV+TDF combination treatment led to a significantly higher rate of virologic response compared to LAM/ LdT+ADV combination treatment in patients with LAM-resistant HBV who had suboptimal responses to LAM/LdT+ADV regardless of HBV genotypic resistance profile (NCT01597934).
Abstract
Background/Aims: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM/LdT+ADV. Methods: This prospective randomized controlled trial examined 91 patients whose serum HBV DNA levels were greater than 60 IU/mL after at least 24 weeks of treatment with LAM/LdT+ADV for LAM-resistant HBV. Patients were randomized to receive a new treatment (ETV+TDF, n=45) or maintained on the same treatment (LAM/LdT+ADV, n=46) for 48 weeks. Patients with baseline ADV resistance were excluded. Results: Compared to LAM/LdT+ADV group, ETV+TDF group had more patients with a virologic response (42/45 [93.33%] vs. 3/46 [6.52%], P<0.001) and had a greater mean reduction in serum HBV DNA level from baseline (-4.16 vs. -0.37 log10 IU/mL, P<0.001). Multivariate analysis indicated that high baseline HBV DNA level (P=0.005) and LAM/LdT+ADV maintenance therapy (P=0.001) were negatively associated with virologic response. At week 48, additional ADV- or ETVassociated mutations were cleared in ETV+TDF group, but such mutations were present in 4.3% of patients in LAM/ LdT+ADV group (P=0.106). The two groups had similar rates of adverse events. Conclusions: ETV+TDF combination treatment led to a significantly higher rate of virologic response compared to LAM/ LdT+ADV combination treatment in patients with LAM-resistant HBV who had suboptimal responses to LAM/LdT+ADV regardless of HBV genotypic resistance profile (NCT01597934).
참고문헌 (38)
- Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
- Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
- European Association For The Study Of The Liver, "EASL clinical practice guidelines: management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B : a 2008 update", Hepatol Int, 2, pp.263~283 (2008)
- Lok AS, "Chronic hepatitis B : update 2009", Hepatology, 50, pp.661~662 (2009)
- Gordon SC, "Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population", Clin Gastroenterol Hepatol, 12, pp.885~893 (2014)
- Eun JR, "Risk assessment for the development of hepatocellular carcinoma : according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virusrelated liver disease", J Hepatol, 53, pp.118~125 (2010)
- Papatheodoridis GV, "Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine", Hepatology, 42, pp.121~129 (2005)
- Yuen MF, "Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease", Antivir Ther, 12, pp.1295~1303 (2007)
- Lok AS, "American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B:update of recommendations", Hepatology, 39, pp.857~861 (2004)
- Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125, pp.1714~1722 (2003)
- Fung SK, "Virologic response and resistance to adefovir in patients with chronic hepatitis B", J Hepatol, 44, pp.283~290 (2006)
- Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B", Hepatology, 45, pp.307~313 (2007)
- Peters MG, "Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B", Gastroenterology, 126, pp.91~101 (2004)
- Fung J, "Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population", Antivir Ther, 12, pp.41~46 (2007)
- Lampertico P, "Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B : from guidelines to field practice", J Hepatol, 50, pp.644~647 (2009)
- Santantonio T, "Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B", Antivir Ther, 14, pp.557~565 (2009)
- Lim YS, "Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside", nucleotide analogues, 2012, pp.17, 53~60
- Petersen J, "Entecavir plus tenofovir combination as rescue therapy in pretreated chronic hepatitis B patients : an international multicenter cohort study", J Hepatol, 56, pp.520~526 (2012)
- Patterson SJ, "Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B", Gut, 60, pp.247~254 (2011)
- Shim JH, "Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone", Hepatology, 50, pp.1064~1071 (2009)
- van Bömmel F, "Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside", nucleotide analogues, 2010, pp.51, 73~80
- 박정길, "Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy", Clinical and Molecular Hepatology, 21(3), pp.242~248 (2015), 대한간학회
- Han KH, "Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B", Antivir Ther, 16, pp.77~87 (2011)
- Lim YS, "Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir", Antimicrob Agents Chemother, 56, pp.2941~2947 (2012)
- Lampertico P, "Low resistance to adefovir combined with lamivudine : a 3-year study of 145 lamivudine-resistant hepatitis B patients", Gastroenterology, 133, pp.1445~1451 (2007)
- Lampertico P, "Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine", Hepatology, 42, pp.1414~1419 (2005)
- Chang TT, "A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients", Gastroenterology, 129, pp.1198~1209 (2005)
- Sherman M, "Entecavir therapy for lamivudine-refractory chronic hepatitis B : improved virologic, biochemical, and serology outcomes through 96weeks", Hepatology, 48, pp.99~108 (2008)
- Kim YJ, "Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures", World J Gastroenterol, 18, pp.6996~7002 (2012)
- 이초이, "Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s", t)ide Treatment Failure, 2014, pp.8(1), 64~69[DOI]
- Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
- Lim YS, "Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure : results of a randomised trial", Gut, 65, pp.852~860 (2016)
- Lim YS, "Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure : results of a randomised trial", Gut, 65, pp.1042~1051 (2016)
- 전희정, "Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir", Clinical and Molecular Hepatology, 23(3), pp.230~238 (2017), 대한간학회[DOI]
- Lilian Yan Liang, "Unmet need in chronic hepatitis B management", Clinical and Molecular Hepatology, 25(2), pp.172~180 (2019), 대한간학회
- Lee YB, "Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?", Clin Mol Hepatol, 23, pp.219~221 (2017)
- Buti M, "Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients", J Hepatol, 47, pp.366~372 (2007)